Insider Selling: Masimo Co. (NASDAQ:MASI) Director Sells 2,053 Shares of Stock

Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares in the company, valued at $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Masimo Stock Performance

MASI opened at $168.21 on Monday. The stock has a market capitalization of $9.07 billion, a price-to-earnings ratio of 116.01 and a beta of 1.04. The company has a fifty day moving average of $174.84 and a 200 day moving average of $157.94. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million during the quarter, compared to analysts’ expectations of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. As a group, sell-side analysts forecast that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Masimo

Institutional investors and hedge funds have recently made changes to their positions in the business. Jones Financial Companies Lllp purchased a new position in shares of Masimo in the 4th quarter worth $27,000. UMB Bank n.a. grew its stake in shares of Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 123 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 71 shares in the last quarter. Trust Co. of Vermont purchased a new position in shares of Masimo in the 4th quarter worth $33,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 64 shares in the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on MASI shares. Wells Fargo & Company increased their price target on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Piper Sandler raised their price objective on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Stifel Nicolaus restated a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Raymond James raised their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.